HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a $60 price target.
July 23, 2024 | 5:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Arrowhead Pharma and maintained a $60 price target.
The reiteration of a Buy rating and the maintenance of a $60 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100